Lincoln Pharmaceuticals declared a final dividend of ₹1.80 per equity share for the financial year ended March 31, 2026. This payout was approved by shareholders during the company's 32nd Annual General Meeting held on September 30, 2026.

The meeting, conducted via video conferencing, saw members adopt the audited standalone and consolidated financial statements for FY26. The board also re-appointed Mr. Hashmukh I. Patel and Mr. Munjal Mahendrabhai Patel as directors following their retirement by rotation. Additionally, the remuneration of cost auditors M/s. Kiran J. Mehta & Co. was ratified at ₹2,50,000 per annum plus applicable taxes.

Voting Results and Approvals

All five resolutions proposed at the AGM were passed with the requisite majority. The voting pattern showed strong shareholder support for financial adoption and director appointments, with dissenting votes remaining negligible or under 5% across all items.

Operational Updates Shared at AGM

During the meeting, Managing Director Mahendra G. Patel provided an overview of recent operational developments. Key highlights included:

• The launch of four new divisions in the domestic market.
• Growth in export volumes alongside expanded manufacturing capacity.
• Operational status of the Mehsana plant and the new API facility at Khatraj.
• Sustainability initiatives where wind and solar projects meet 100% of the company's energy requirements.

The MD noted that international markets contributed approximately 62% to total sales, while domestic markets accounted for 38%.

What the Numbers Show

The voting data reveals a clear distinction in shareholder sentiment between routine administrative approvals and governance-related appointments. While the declaration of the dividend and the ratification of auditor fees received near-unanimous support (100.00% assent), the re-appointment of directors Hashmukh I. Patel and Munjal M. Patel saw a dissent rate of approximately 4.5% each. This divergence suggests that while shareholders are aligned with financial distributions and compliance matters, there is a minor segment of the investor base that may have reservations regarding specific board compositions, although this did not impede the passage of the resolutions.

Lincoln Pharmaceuticals Limited shareholders approved the declaration of a final dividend of ₹1.80 per equity share for FY26 during its 32nd Annual General Meeting (AGM) held on September 30, 2026.

The meeting was conducted through Video Conferencing and Other Audio-Visual Means in compliance with Ministry of Corporate Affairs and SEBI circulars. Voting results were submitted to stock exchanges on October 3, 2026, pursuant to Regulation 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dividend and Financial Statements Approval

Shareholders voted overwhelmingly in favor of adopting the audited standalone and consolidated financial statements for the financial year ended March 31, 2026. The resolution received 99.99% votes in favor across all shareholder categories.

The proposal to declare a dividend of ₹1.80 per equity share of ₹10 each (18% of face value) was also passed with near-unanimous support. Public institutions cast 5,10,418 votes in favor with zero dissent, while public non-institutional shareholders recorded 13,86,126 votes in favor against just 45 dissenting votes.

Director Reappointments Face Institutional Dissent

Two directors retiring by rotation were reappointed, though institutional investors registered significant dissent on both resolutions. Hashmukh I. Patel was reappointed with 95.47% overall support, while Munjal Mahendrabhai Patel secured 95.48% support.

What the Numbers Show

A clear divergence exists between promoter and institutional voting patterns regarding director reappointments. While promoters voted unanimously in favor of both directors, public institutions opposed approximately 99% of their polled votes on these specific resolutions. For Hashmukh I. Patel, institutions cast 5,06,936 votes against versus only 3,482 in favor. Similarly, for Munjal Mahendrabhai Patel, institutional dissent stood at 5,06,544 votes against compared to 3,874 in favor. This pattern suggests institutional investors may have governance concerns or proxy advisor recommendations influencing their voting behavior on board composition, despite the resolutions passing comfortably due to promoter majority support.

Other Approvals

The AGM also ratified the remuneration payable to cost auditors for FY27, which passed with 100.00% votes in favor among public institutions and negligible dissent from non-institutional shareholders. The scrutinizer’s report confirmed that all resolutions were passed with the requisite majority as ordinary resolutions.